Abstract
Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis and is essential for normal embryonic development and many physiological events that require the growth of new blood vessels. Abnormal expression of endogenous VEGF can lead to ocular diseases including age related macular degeneration (Ohno-Matsui et al., 2001) and diabetic retinopathy (Aiello et al., 1994; Boulton et al., 1998), which are the two leading causes of blindness in the developed world. Regulation of VEGF expression occurs primarily through trans-factor interactions with cis-elements located on the 5′ and 3′ untranslated regions (UTR’s) and include stabilizing and destabilizing elements in addition to enhancer regions (Coles et al., 2004; Dibbens et al., 1999; Iida et al., 2002; Levy et al., 1997; Marano et al., 2004). The prime stimuli of VEGF upregulation are hypoxic or ischemic conditions, which indirectly activates VEGF through interactions between hypoxia inducible factor 1 (HIF-1) and the hypoxia response element (HRE) located within the promoter region of the VEGF gene (Forsythe et al., 1996).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adamis, A. P., Shima, D. T., Tolentino, M. J., Gragoudas, E. S., Ferrara, N., Folkman, J., D’Amore, P. A., Miller, J. W., 1996, Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate, Arch Ophthalmol, 114:66–71.
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al., 1994, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N Engl J Med, 331:1480–1487.
Akiyama, H., Tanaka, T., Itakura, H., Kanai, H., Maeno, T., Doi, H., Yamazaki, M., Takahashi, K., Kimura, Y., Kishi, S., Kurabayashi, M., 2004, Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo. Invest Ophthalmol Vis Sci, 45:1289–1296.
Arenz, C., Schepers, U., 2003, RNA interference: from an ancient mechanism to a state of the art therapeutic application? Naturwissenschaften, 90:345–359.
Auricchio, A., Behling, K. C., Maguire, A. M., O’Connor, E. M., Bennett, J., Wilson, J. M., Tolentino, M. J., 2002, Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents, Mol Ther, 6:490–494.
Bainbridge, J. W., Mistry, A., Binley, K., De Alwis, M., Thrasher, A. J., Naylor, S., Ali, R. R., 2003, Hypoxiaregulated transgene expression in experimental retinal and choroidal neovascularization. Gene Ther, 10:1049–1054.
Bainbridge, J. W., Mistry, A., De Alwis, M., Paleolog, E., Baker, A., Thrasher, A. J., Ali, R. R., 2002, Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther, 9:320–326.
Baum, C., von Kalle, C., Staal, F. J., Li, Z., Fehse, B., Schmidt, M., Weerkamp, F., Karlsson, S., Wagemaker, G., Williams, D. A., 2004, Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther, 9:5–13.
Berdugo, M., Valamanesh, F., Andrieu, C., Klein, C., Benezra, D., Courtois, Y., Behar-Cohen, F., 2003, Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev, 13:107–114.
Boulton, M., Foreman, D., Williams, G., McLeod, D., 1998, VEGF localisation in diabetic retinopathy. Br J Ophthalmol, 82:561–568.
Coles, L. S., Bartley, M. A., Bert, A., Hunter, J., Polyak, S., Diamond, P., Vadas, M. A., Goodall, G. J., 2004, A multi-protein complex containing cold shock domain (Y-box) and polypyrimidine tract binding proteins forms on the vascular endothelial growth factor mRNA. Potential role in mRNA stabilization. Eur J Biochem, 271:648–660.
de Boer, R. A., Siebelink, H. J., Tio, R. A., Boomsma, F., van Veldhuisen, D. J., 2001, Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail, 3:331–333.
Dibbens, J. A., Miller, D. L., Damert, A., Risau, W., Vadas, M. A., Goodall, G. J., 1999, Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell, 10:907–919.
Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., Semenza, G. L., 1996, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol, 16:4604–4613.
Garrett, K. L., Shen, W. Y., Rakoczy, P. E., 2001, In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J Gene Med, 3:373–383.
Iida, K., Kawakami, Y., Sone, H., Suzuki, H., Yatoh, S., Isobe, K., Takekoshi, K., Yamada, N., 2002, Vascular endothelial growth factor gene expression in a retinal pigmented cell is up-regulated by glucose deprivation through 3′ UTR. Life Sci, 71:1607–1614.
Lai, C. M., Brankov, M., Zaknich, T., Lai, Y. K., Shen, W. Y., Constable, I. J., Kovesdi, I., Rakoczy, P. E., 2001, Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther, 12:1299–1310.
Lai, Y. K., Shen, W. Y., Brankov, M., Lai, C. M., Constable, I. J., Rakoczy, P. E., 2002, Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther, 9:804–813.
Levy, N. S., Goldberg, M. A., Levy, A. P., 1997, Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim Biophys Acta, 1352:167–173.
Marano, R. J., Wimmer, N., Kearns, P. S., Thomas, B. G., Toth, I., Brankov, M., Rakoczy, P. E., 2003, Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Experimental Eye Research, Accepted.
Marano, R. J., Brankov, M., Rakoczy, P. E., 2004, Discovery of a novel control element within the 5′UTR of VEGF: Regulation of expression using sense oligonucleotides. J Biol Chem, 279(36):37808–37814.
Ohno-Matsui, K., Morita, I., Tombran-Tink, J., Mrazek, D., Onodera, M., Uetama, T., Hayano, M., Murota, S. I., Mochizuki, M., 2001, Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol, 189:323–333.
Reich, S. J., Fosnot, J., Kuroki, A., Tang, W., Yang, X., Maguire, A. M., Bennett, J., Tolentino, M. J., 2003, Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis, 9:210–216.
The Eyetech Study Group, 2002, Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration, Retina, 22:143–152.
The Eyetech Study Group, 2003, Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology, 110:979–986.
Tolentino, M. J., Brucker, A. J., Fosnot, J., Ying, G. S., Wu, I. H., Malik, G., Wan, S., Reich, S. J., 2004, Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina, 24:132–138.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Marano, R.J., Rakoczy, P.E. (2006). Controlling Vascular Endothelial Growth Factor: Therapies for Ocular Diseases Associated with Nevascularization. In: Hollyfield, J.G., Anderson, R.E., LaVail, M.M. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 572. Springer, Boston, MA. https://doi.org/10.1007/0-387-32442-9_42
Download citation
DOI: https://doi.org/10.1007/0-387-32442-9_42
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-28464-4
Online ISBN: 978-0-387-32442-5
eBook Packages: MedicineMedicine (R0)